Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction
Amedeo Lonardo, Ashwani K. Singal, Natalia A. Osna, et al.
Metabolism and Target Organ Damage (2022) Vol. 2, pp. 12-12
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance
Alan L. Hutchison, Federica Tavaglione, Stefano Romeo, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 6, pp. 1524-1541
Open Access | Times Cited: 90
Widespread occurrence of two typical N, N’-substituted p-phenylenediamines and their quinones in humans: Association with oxidative stress and liver damage
Shiming Song, Yanxia Gao, Shuai Feng, et al.
Journal of Hazardous Materials (2024) Vol. 468, pp. 133835-133835
Closed Access | Times Cited: 37
Global prevalence of nonalcoholic fatty liver disease: an updated meta-analysis on 78 million population over 38 countries
Ehsan Amini‐Salehi, Negin Letafatkar, Naeim Norouzi, et al.
Archives of Medical Research (2024) Vol. 55, Iss. 6, pp. 103043-103043
Closed Access | Times Cited: 37
NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care
Piero Portincasa
Internal and Emergency Medicine (2023) Vol. 18, Iss. 4, pp. 993-1006
Open Access | Times Cited: 26
Endpoints in NASH Clinical Trials: Are We Blind in One Eye?
Amedeo Lonardo, Stefano Ballestri, Alessandro Mantovani, et al.
Metabolites (2024) Vol. 14, Iss. 1, pp. 40-40
Open Access | Times Cited: 13
Relationship between Helicobacter pylori infection and risk of metabolic dysfunction‐associated steatotic liver disease: An updated meta‐analysis
Alessandro Mantovani, Maria Giovanna Lando, Nicolò Diego Borella, et al.
Liver International (2024) Vol. 44, Iss. 7, pp. 1513-1525
Open Access | Times Cited: 9
Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review
Amedeo Lonardo
Metabolism and Target Organ Damage (2024) Vol. 4, Iss. 2
Open Access | Times Cited: 9
Thyroid function, adipokines and mitokines in metabolic dysfunction‐associated steatohepatitis: A multi‐centre biopsy‐based observational study
Matina Kouvari, Laura Valenzuela‐Vallejo, Evangelos Axarloglou, et al.
Liver International (2024) Vol. 44, Iss. 3, pp. 848-864
Open Access | Times Cited: 7
Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort
Liang‐Jie Tang, Dan‐Qin Sun, Sherlot Juan Song, et al.
Liver International (2024) Vol. 44, Iss. 5, pp. 1129-1141
Closed Access | Times Cited: 5
Perspective article: determinants and assessment of cardiovascular risk in steatotic liver disease owing to metabolic dysfunction-addressing the challenge
Mohamad Jamalinia, Amedeo Lonardo
Metabolism and Target Organ Damage (2024) Vol. 4, Iss. 3
Open Access | Times Cited: 5
The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis
Xiaoyan Li, Jie He, Qiuhua Sun
Clinical Nutrition (2024) Vol. 43, Iss. 9, pp. 2005-2016
Open Access | Times Cited: 5
Liver fibrosis as a barometer of systemic health by gauging the risk of extrahepatic disease
Amedeo Lonardo, Stefano Ballestri, György Baffy, et al.
Metabolism and Target Organ Damage (2024) Vol. 4, Iss. 4
Open Access | Times Cited: 5
Deciphering the role of aberrant DNA methylation in NAFLD and NASH
Meenakshi Vachher, Savita Bansal, Bhupender Kumar, et al.
Heliyon (2022) Vol. 8, Iss. 10, pp. e11119-e11119
Open Access | Times Cited: 19
Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms
Simonetta Lugari, Enrica Baldelli, Amedeo Lonardo
Metabolism and Target Organ Damage (2023) Vol. 3, Iss. 1, pp. 5-5
Open Access | Times Cited: 12
The heterogeneity of metabolic syndrome presentation and challenges this causes in its pharmacological management: a narrative review focusing on principal risk modifiers
Amedeo Lonardo
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 10, pp. 891-911
Closed Access | Times Cited: 12
Endogenous sex hormones and nonalcoholic fatty liver disease in US adults
Donghee Kim, Richie Manikat, George Cholankeril, et al.
Liver International (2023) Vol. 44, Iss. 2, pp. 460-471
Closed Access | Times Cited: 11
Retinopathy as a predictive indicator for significant hepatic fibrosis according to T2DM status: A cross-sectional study based on the national health and nutrition examination survey data
Jinze Li, Yi Xiang, Jiahao Han, et al.
Annals of Hepatology (2024) Vol. 29, Iss. 4, pp. 101478-101478
Open Access | Times Cited: 4
Metabolic obesity phenotypes and all-cause mortality among the Chinese oldest-old population: a prospective cohort study
Wei-Qi Song, Wen-Fang Zhong, Jian Gao, et al.
International Journal of Obesity (2024)
Closed Access | Times Cited: 4
Updated recommendations for the management of metabolic dysfunction–associated steatotic liver disease (MASLD) by the Latin American working group.
Luis Antonio Díaz, Juan Pablo Arab, Francisco Idalsoaga, et al.
Annals of Hepatology (2025), pp. 101903-101903
Open Access
Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies
George Agyapong, Farzaneh Dashti, Bubu A. Banini
Annals of the New York Academy of Sciences (2023) Vol. 1526, Iss. 1, pp. 16-29
Open Access | Times Cited: 9
Gut Microbes, Diet, and Genetics as Drivers of Metabolic Liver Disease: A Narrative Review Outlining Implications for Precision Medicine
Jake B. Hermanson, Samar A. Tolba, Evan A. Chrisler, et al.
The Journal of Nutritional Biochemistry (2024) Vol. 133, pp. 109704-109704
Closed Access | Times Cited: 3
Metabolic bariatric surgery, alcohol misuse and liver cirrhosis: a narrative review
Matthew L. Basa, S. Danielle, David Mitchell, et al.
Metabolism and Target Organ Damage (2024) Vol. 4, Iss. 3
Open Access | Times Cited: 3
FIB-4 is closer to FibroScan screen results to detecting advanced liver fibrosis and maybe facilitates NAFLD warning
Yuping Ding, Zuoyu Wang, Haiyan Niu, et al.
Medicine (2023) Vol. 102, Iss. 34, pp. e34957-e34957
Open Access | Times Cited: 7
Childhood maltreatment and risk of metabolic dysfunction-associated steatotic liver disease – Evidence of sex-specific associations in the general population
Ulrike Siewert‐Markus, Till Ittermann, Johanna Klinger-König, et al.
Journal of Psychosomatic Research (2024) Vol. 183, pp. 111829-111829
Open Access | Times Cited: 2
Extra-hepatic cancers in metabolic fatty liver syndromes
Amedeo Lonardo
(2023), pp. 11-17
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top